Of special interest, tumor expression of PD-L1 and tumor-infiltrating lymphocyte expression of PD-1 are seen in 27% and 48% of tumors, suggesting gliomas as a promising potential tumor type for immune modulatory agents [32]; identification of BRCA1/2 mutations makes potential usage of PARP inhibitors of particular interest [33]; the known high rate of EGFR aberration in GBM was also shown by multiple platforms including IHC, ISH, fragment analysis (for EGFRvIII) and NextGen sequencing (for point mutations and small in-dels), confirming EGFR as an important therapeutic target in GBM [3, 34]. The gene discussed is BRCA1; the disease is central nervous system cancer.